Nephrotic syndrome and renal failure in a patient with metastatic breast cancer

Yoshizawa, Hiromichi; Akimoto, Tetsu; Nishino, Katsuhiko; Ito, Chiharu; Takeda, Shin‐ichi; Kotoda, Atsushi; Tamba, Kaichiro; Yumura, Wako; Muto, Shigeaki; Ueda, Yoshihiko; Kusano, Eiji

doi:10.1007/s10157-011-0425-1

Cited by 5 publications

(3 citation statements)

References 25 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Since this initial report, several additional case reports and series have confirmed this association. 38,39 Zoledronate is another bisphosphonate that is usually associated with acute tubular injury. However, there are rare case reports associating zoledronate and C-FSGS.…”

Section: Conventional Chemotherapy and C-fsgsmentioning

confidence: 99%

See 1 more Smart Citation

Cancer drugs and the glomerulus

Shah

Uppal

Perazella

2018

Journal of Onco-Nephrology

View full text Add to dashboard Cite

Several chemotherapeutics including novel immunotherapies and targeted therapies have recently been approved for the treatment of various cancers. Several nephrotoxicities secondary to treatment with chemotherapeutics have been described in patients with cancer. Acute kidney injury from acute tubular necrosis and acute interstitial nephritis is commonly reported nephrotoxicities following treatment with cancer drugs. Although less common, several glomerular lesions include minimal change disease, collapsing and non-collapsing focal segmental glomerulosclerosis secondary to chemotherapy-related podocyte injury have been reported in the literature. In addition to conventional chemotherapeutics, several novel cancer drugs including immune point check inhibitors, anti-vascular endothelial growth factor inhibitors, and tyrosine kinase inhibitors have also been associated with various glomerular lesions. While the occurrence of glomerular toxicities related to cancer drugs is less common than tubular injury, failure to recognize these associations may lead to poor renal outcome. In this article, we review several chemotherapy-related glomerular diseases including thrombotic microangiopathy.

show abstract

Section: Conventional Chemotherapy and C-fsgsmentioning

confidence: 99%

“…37 Since this initial report, several additional case reports and series have confirmed this association. 38,39…”

Section: Cancer Drugs and Collapsing Focal Segmental Glomerulosclerosismentioning

confidence: 99%

Cancer drugs and the glomerulus

Shah

Uppal

Perazella

2018

Journal of Onco-Nephrology

View full text Add to dashboard Cite

show abstract

“…Interestingly, the presumable association between the development of minimal change nephrotic syndrome and ovarian carcinoma has been described anecdotally (13). Although the relationship between malignancies and nephrotic glomerulopathies is difficult to prove, it has been suggested by clinical characteristics such as a close temporal link and parallel evolution, including improvement, resolution, and relapse (14)(15)(16). In this context, the fact that the malignant ascites had gradually developed despite the remission of nephrotic syndrome led us to consider that the presence of a latent relationship between minimal change nephrotic syndrome and peritoneal malignancy was unlikely, at least in the current patient.…”

Section: A Bmentioning

confidence: 99%

Minimal Change Nephrotic Syndrome Complicated with Malignant Ascites in a Patient with Type II Diabetes

et al. 2012

Self Cite

View full text Add to dashboard Cite

A large number of renal biopsy studies have shown the concurrent presence of non-diabetic renal disease in diabetics. This report describes one such diabetic female patient with nephrotic syndrome due to minimal change glomerular disease who was successfully treated with prednisolone. Despite the remission of her nephrotic syndrome, she had gradual development of malignant ascites, which was finally interpreted to be linked to primary peritoneal carcinoma. It is necessary to bear in mind that malignancies may not only be the underlying etiology for paraneoplastic glomerular injuries, but also can be an independent pathogenic process, regardless of their nephrotic status during the overall management of the patients with ascites.

show abstract

Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease

et al. 2016

View full text Add to dashboard Cite

Cancer patients with severe renal dysfunction represent a challenge for the physician. This is the first case report on the use of denosumab in a dialysis patient with bone metastases. We present the clinical case of a 45-year-old woman who had hepatorenal polycystic disease, diagnosed during childhood, and stage IV chronic kidney failure at the time of breast cancer diagnosis. Three years after surgery plus adjuvant hormonal therapy she suffered a further worsening of renal function, requiring dialysis, and very advanced bone metastasis in the hip with severe pain. As pamidronate was the only bone agent available in the center, she received it for 4 months (before a dialysis session), during which time the bone metastases stabilized. In March 2014, the patient switched to denosumab (which had become available in the center), and continued with hormone therapy. Seven months after denosumab initiation, the patient had almost complete pain relief, and the bone metastases exhibited radiological improvement. The tolerability was excellent, without any related adverse event. There were no changes in albumin-adjusted serum calcium, serum phosphorus, and intact parathyroid hormone, except for a transient and mild hypocalcemia at 3 months and an increase in intact parathyroid hormone levels, which required adjustment of vitamin D analog dose. Denosumab can be administered to prevent skeletal-related events in patients with bone metastasis from solid tumors and severely impaired renal function, even in those requiring dialysis. In this particular patient, the safety was good.

show abstract

Nephrotic syndrome and renal failure in a patient with metastatic breast cancer

Cited by 5 publications

References 25 publications

Cancer drugs and the glomerulus

Cancer drugs and the glomerulus

Minimal Change Nephrotic Syndrome Complicated with Malignant Ascites in a Patient with Type II Diabetes

Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease

Contact Info

Product

Resources

About